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ABSTRACT
Objective To investigate the intention of the Hong Kong
general population to take up vaccination against
influenza A/H1N1.
Setting Cross sectional population based anonymous
survey.
ParticipantsRandomsampleof301adultsinterviewedby
telephone (response rate 80%).
Main outcome measure Intention to take up vaccination
against influenza A/H1N1 under five hypothetical
scenarios: vaccination is free; vaccination per dosage
costs less than $HK100 (£8; €9; $13), $HK101-200, or
more than $HK200; and no data are available on the
efficacy and safety of the vaccine.
Results 45% (n=135) of the participants reported that
they would be highly likely take up vaccination if it was
free. When vaccination incurred a cost, however, the
prevalenceofuptakedecreased:36%(n=108)wouldtake
upvaccinationifitcostlessthan$HK100,24%(n=72)ifit
cost $HK101-200, and 15% (n=45) if it cost more than
$HK200; and in absence of proved efficacy and safety
decreased to 5% (n=14). Moreover, 32% (n=95)
considered universal A/H1N1 vaccination unnecessary.
Overall, 39% (n=117) of participants believed that
A/H1N1 vaccination would prevent the virus being
contracted; 63% (n=189) erroneously believed that
efficacy of the vaccine had been confirmed by clinical
trials, and 16% (n=49) believed that it is necessary for
everyone in Hong Kong to take up vaccination against
influenza A/H1N1.
Conclusions The uptake of vaccination against influenza
A/H1N1 by the general population of Hong Kong is
unlikely to be high and would be sensitive to personal
cost. Evidence about safety and efficacy is critical in
determining the prevalence of uptake of vaccination.
INTRODUCTION
The earliest confirmed case of influenza A/H1N1
(swine flu) in 2009 was reported in Mexico on 23
April,
1 and the World Health Organization declared
the disease to be a pandemic on 11 June.
2 As of 13
September 2009 the virus has spread to over 170
countries, territories, and areas, and is estimated to
have caused over 3486 deaths.
3 The mortality from
A/H1N1 appears moderate, although the virus does
seem to be more infectious than seasonal influenza
4
and children are particularly susceptible.
5 On 20 Sep-
tember, 22054 cases of influenza A/H1N1 and 15
associated deaths were confirmed in Hong Kong.
6
Thegovernmenthasnowsuspendedthe testingofsus-
pected cases. The development of A/H1N1 vaccines
would be one of the most effective ways to control the
pandemic.
7 Many governments have announced large
scale plans for vaccination against influenza A/H1N1.
On 19 June 2009 the government of Hong Kong
passed legislation to purchase five million doses of
influenza A/H1N1 vaccine and indicated that a large
scale vaccination campaign would be launched at the
end of the year,
89 with an acknowledgement that the
vaccinemightnothavegonethroughcompleteclinical
trials. The government announced that the vaccine
would be provided to a high risk group of two million
people, including healthcare workers, people aged
more than 65, children aged 6 months to 6 years, and
those with particular health conditions, along with
500000 people who would voluntarily pay for the
service.
10 The tender was unsuccessful and a new
roundof biddingwasinitiated. Thecost of vaccination
has not yet been agreed.The market price forseasonal
influenzavaccinationinHongKongisaroundUS$20-
25 (£13-16; €14-17).
Arecentstudyreportedthat48%ofhealthcarework-
ersinHongKongwerewillingtoacceptvaccinationat
the prepandemic phase of the influenza A/H1N1 epi-
demic and that the perceived risk of contracting the
virus and history of vaccination against seasonal influ-
enza were associated with the willingness to take up
vaccination, whereas fear of side effects and doubts
about vaccine efficacy were major reasons for
unwillingness.
11
The uptake of seasonal influenza vaccination in
Hong Kong during September 2006 to April 2007
among community dwelling older people aged 65 or
more was 35% and it was lower among pregnant
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BMJ | ONLINE FIRST | bmj.com page 1 of 6women (4%), children aged 6-23 months (9%), those
with chronic diseases (23%), and adults in the general
population (15%).
12 We investigated the intention of
taking up vaccination against influenza A/H1N1
under five hypothetical scenarios including cost and
availability of clinical evidence on the vaccine.
METHODS
The target population was Chinese adults aged
between 18 and 60 who lived in Hong Kong. The
study was carried out during 2-8 July 2009, after influ-
enza A/H1N1 had been declared a pandemic (11
June),
2 the first community infected case had been
reported (10 June),
13 and before the first reported
death associated with the virus in Hong Kong (27
July).
14
We carried out telephone surveys by using a struc-
tured questionnaire. Study methods were similar to
those used in local studies related to severe acute
respiratory syndrome,
15-19 avian flu,
20-22 and influenza
A/H1N1.
23 Telephone numbers were randomly
selected from current telephone directories; over 95%
of households in Hong Kong have a telephone line
installed.
2425 Interviews were done from 6 30 pm to
10 pm to avoid over-representation of people not
working. An eligible member was selected from each
of the contacted households. If more than one house-
hold member was eligible, we invited the one whose
birthdaywasclosesttothesurveydatetojointhestudy.
Verbalconsentwasobtainedfromtheparticipantsand
the interview took about 20 minutes. At least three tel-
ephone calls were made at different hours and week-
daysbeforeweconsideredthenumbertobeinvalid.A
total of 378 eligible participants were identified and
301 completed the interview; the response rate was
80% (301/378).
Outcome measures and data analysis
Thequestionnaireitemsweremodifiedfromthosethat
had been used in some of the studies onavian flu
212627
and a study on influenza A/H1N1.
23 Participants were
askedsequentiallyaboutintentionstotakeupvaccina-
tionagainstinfluenzaA/H1N1underfivehypothetical
scenarios: vaccination is free; vaccination per dosage
costs less than $HK100, $HK101-200, or more than
$HK200; and clinical data are lacking on vaccine effi-
cacyandsafety.Responsecategoriesincludedunlikely
(certainly not, mostly not), unsure, and highly likely
(mostly and definitely). As a reference, the median
familyincomeinHongKongin2006wasaround$HK
17250.
28
Participantswereaskedwhetherclinicalevidenceon
the safety and efficacy of the influenza A/H1N1 vac-
cine was currently available. Other questions were
related to knowledge about different modes of trans-
missions of the virus and perceptions related to the
virus and its vaccine.
We tabulated the distributions of several variables.
Analyses were carried out in SPSS version 16.0.
RESULTS
Of the 301 participants, 55% (n=165) were women,
47% (n=140) were aged less than 40, 37% (n=111)
had received some education after secondary school,
and 63% (n=189) were married or cohabiting. Twenty
per cent of the participants (n=61) self reported ever
receiving vaccination against seasonal influenza
(table 1).
Perceptions towards vaccination against influenza A/H1N1
Intentions—When the participants were asked about
theirintentiontotakeupfreevaccinationagainstinflu-
enza A/H1N1, 45% (n=135) thought it highly likely
Table 1 |Characteristics of participants and intention to take up vaccination against influenza
A/H1N1 according to five hypothetical scenarios
Variables
No (%) of participants
(n=301)
Men 136 (45)
Women 165 (55)
Age (years):
<30 76 (25)
30-39 64 (21)
40-49 86 (29)
50-60 75 (25)
Education level*:
Form 3 or below 58 (19)
Form 4—matriculation 130 (44)
College or above 111 (37)
Marital status:
Single 105 (35)
Married or cohabiting 189 (63)
Divorced or widowed 5 (2)
Full time employment:
No 123 (41)
Yes 177 (59)
Ever had influenza vaccination:
No 240 (80)
Yes 61 (20)
Hypothetical scenarios for influenza A/H1N1 vaccination
Vaccination is free:
Unlikely or unsure† 166 (55)
Highly likely‡ 135 (45)
Vaccination costs <$HK100:
Unlikely or unsure† 193 (64)
Highly likely‡ 108 (36)
Vaccination costs $HK101-200:
Unlikely or unsure† 229 (76)
Highly likely‡ 72 (24)
Vaccination costs >$HK200:
Unlikely or unsure† 256 (85)
Highly likely‡ 45 (15)
Vaccine efficacy and safety have not been confirmed by clinical trials:
Unlikely or unsure† 287 (95)
Highly likely‡ 14 (5)
Based on census data to end of 2008 from Census and Statistics Department Hong Kong, 2009. 46% of men
and 54% of women were aged 18-60; 25% of participants were aged <30, 24% were aged 30-39, 27% were
aged 40-49, and 24% were aged 50-60.
*Form 3 is equivalent to ninth year of formal education and form 4 to 10th year. On completion of 11 years of
formal education, students are required to take the two year matriculation programme to enter universities.
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unlikely or were unsure (mostly not, certainly not, or
unsure). The prevalence of intention (highly likely to
take up the vaccine), however, decreased with increas-
ing cost in the hypothetical scenarios where a charge
was levied for vaccination: 36% (n=108) were highly
likely to take up vaccination for less than $HK100,
24% (n=72) for $HK101-200, and 15% (n=45) for
more than $HK200. In the absence of data on efficacy
and safety the prevalence decreased to 5% (n=14;
table 1).
Positiveandnegativeattitudes—39%(n=117)ofpartici-
pants believed that vaccination would be effective at
preventing influenza A/H1N1, 63% (n=189) erro-
neously believed that efficacy of influenza A/H1N1
vaccine had been confirmed by clinical trials, and
16% (n=49) believed that it is necessary for everyone
in Hong Kong to take up vaccination against influenza
A/H1N1 (49%, n=146, not quite necessary and 32%,
n=95, completely unnecessary; table 2). Overall, 27%
(n=81) of the participants believed vaccination against
influenza A/H1N1 would be inconvenient and 16%
(n=49) believed that it would cause quite a lot of side
effectsorthatsideeffectswouldbeverysevere(table 2).
Knowledge and perceptions about influenza A/H1N1
Knowledge—51% (n=153) of the participants gave cor-
rect responsesto all threequestionson modesof trans-
mission through droplets, bodily contact with infected
people,andtouchingobjectscontaminatedwiththeA/
H1N1 virus (table 2).
Perceived severity—30% (n=90) of the participants
erroneously believed that the fatality associated with
A/H1N1 among adults exceeded 1%; 14% (n=41)
believed that A/H1N1 results in severe and irreversi-
ble damage to the body among adults; 13% (n=37)
believed that more than 10 deaths related to A/H1N1
infectionwouldoccurinHongKong,and40%(n=118)
believed that there are quite a lot or many hidden
H1N1casesofinfluenzaA/H1N1inthelocal commu-
nity (table 2). Compared with seasonal flu, less than
half of the participants believed that A/H1N1 would
result in a higher fatality rate (36%, n=108), higher
infectivity (42%, n=126), and more severe bodily
damage (33%, n=95; table 2).
Riskperception—Around10%oftheparticipantscon-
sideredthemselves(10%, n=31),theirfamilymembers
(10%, n=30),or the generalpublic (12%, n=35)to have
a high or very high chance of contracting A/H1N1 in
the next year, and 28% perceived a high (high, very
high, or certain) chance of having a large scale out-
break of influenza A/H1N1 in the coming year
(table 2).
DISCUSSION
A vaccine against influenza A/H1N1 will become
available in the near future. Over 30 governments
placed orders for vaccines by June 2009
29: the United
Kingdom ordered enough to cover its entire
population,
30 Japan intended to provide enough for
Table 2 |Participants’ knowledge and perceptions of influenza A/H1N1 and its vaccine
Variables
No (%) of participants
(n=301)
Knowledge on modes of transmission
Correct knowledge about modes of transmission:
Could be transmitted via droplets (for example, sneezing) 291 (97)
Could be transmitted via touching body of infected person 203 (67)
Could be transmitted via touching contaminated objects 196 (65)
All above items are correct:
No 148 (49)
Yes 153 (51)
Perceptions related to severity of influenza A/H1N1
Fatality rate for adults:
<1% 181 (60)
1-5% 67 (22)
>5% 23 (8)
Don’tk n o w 30 (10)
Would cause severe and irreversible damage to body of adults:
Disagree 232 (77)
Agree 41 (14)
Don’tk n o w 28 (9)
No of deaths in Hong Kong in coming year:
None 87 (30)
1-10 162 (57)
11-50 32 (11)
>50 5( 2 )
No of hidden cases in community:
Very few 56 (19)
Af e w 121 (41)
Quite a lot or many 118 (40)
Chance of having large scale local outbreak of influenza A/H1N1 in coming year:
Unlikely, most unlikely, certainly not, unsure 218 (72)
Certainly, most likely, likely 83 (28)
Risk perception
High or very high chance of contracting influenza A/H1N1 in coming year:
Participant 31 (10)
Family members 30 (10)
General public 35 (12)
Comparisons of influenza A/H1N1 to seasonal influenza
Fatality rate:
Much lower, a little lower, or same 190 (64)
A bit higher or much higher 108 (36)
Transmission rate:
Much lower, a little lower, same 173 (58)
A bit higher or much higher 126 (42)
Severity of damage to body:
Much lower, a little lower, same 196 (67)
A bit higher or much higher 95 (33)
Perceptions related to influenza A/H1N1 vaccine
Vaccination is inconvenient:
Disagree, strongly disagree, unsure 219 (73)
Agree or strongly agree 81 (27)
Vaccine is effective for prevention of influenza A/H1N1:
Disagree, strongly disagree, or unsure 183 (61)
Agree or strongly agree 117 (39)
Efficacy of present A/H1N1 vaccine has been confirmed by clinical trials:
No 44 (15)
Yes 189 (63)
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31 and Australia orderedenough for
half its population.
32 It is uncertain whether the early
production of vaccine could meet the demands of dif-
ferentcountries.
31Manygovernmentsthereforeintend
to provide A/H1N1 vaccine to a substantial propor-
tion of the general population. A few countries are
more conservative—the US government will confirm
the proportion of citizens who need to be vaccinated
after the completion of clinical trials,
7 whereas main-
land China plans to provide vaccines for 5% of its
population.
31 Most of the governments have not
announced the pricing schemes.
Our results are comparable to those of a study in
health workers,
11 with a similar prevalence for inten-
tion to take up A/H1N1 vaccination when it was free
(48%v45%).Lackofdataonsafetyandefficacywasthe
reason for health workers’ unwillingness to take up
vaccination. No trials have studied the responsiveness
of the general population. Our results show that inten-
tion to take up A/H1N1 vaccination would be highly
sensitivetocostaswellastotheavailabilityofscientific
evidenceonitsefficacyandsafety.Asthepopulationof
Hong Kong is seven million, the Hong Kong govern-
ment plans to purchase five million doses of the A/
H1N1 vaccine. The actual demand would depend on
the cost and, more importantly, the availability of clin-
ical evidence on efficacy and safety. Without such an
assurance the prevalence of uptake of vaccination in
the general population would be lower than 5%. It is
notknownwhethertheprevalenceforhighriskgroups
would be different but previous data showed that,
except for elderly people, the prevalence of vaccina-
tion against seasonal influenza for other risk groups in
Hong Kong tended to be low.
12 There are reasons to
speculate that in the absence of scientific evidence, the
prevalence of uptake of A/H1N1 vaccination in these
high risk groups would remain low.
The intention to take up free vaccination might,
however, be an over-estimation as most of the partici-
pants(63%)erroneouslybelievedthatatthetimeofthe
surveyclinicalevidenceontheefficacyandsafetyofA/
H1N1 vaccine was available. Many of these partici-
pants may change their mind if clinical evidence
remains unavailable when the vaccination campaign
is launched. The publicity that less than half of the
local healthcare workers were willing to take up A/
H1N1 vaccination
11 might also undermine the pub-
lic’s confidence in being vaccinated. The relatively
lowlevelsofpositiveintentiontotakeupA/H1N1vac-
cination in the general population may be partially
explained by the confusion between different types of
influenza related vaccination. A previous study
showed that a high proportion (39%) of the general
public were under the misconception that seasonal
influenza vaccination is effective at preventing influ-
enza A/H1N1.
23 Without clarifying sucha misconcep-
tion, people may resort to seasonal influenza
vaccination,whichhaspassedclinicaltrialsonefficacy
and safety, rather than receiving a new vaccine, espe-
ciallyifithasnotbeenfullytested.Althoughaboutone
third of participants believed that A/H1N1 has a fatal-
ity of more than 1%, that A/H1N1 is more severe than
seasonal flu, and that many hidden cases of A/H1N1
exist in the community, over half of the participants
believed otherwise. Perceived susceptibility was also
relatively low (around 10% perceived susceptibility as
high). Therefore in the context of the study influenza
A/H1N1 was seen by the participants as a relatively
mild disease and that it might not be worth the risk to
be vaccinated against A/H1N1 as it has not been thor-
oughly tested for safety and efficacy.
DespiteHongKongbeingafairlyaffluentcitywitha
highdegreeofvigilanceforA/H1N1,
23acceptabilityof
theA/H1N1vaccinewasstillhighlysensitivetocost.It
is expected that such sensitivity would be even higher
in developing countries and in those countries where
peoplemayfeellessanxiousaboutinfluenzaA/H1N1.
Moreover, since the A/H1N1 vaccine is new, people
worldwide are curious about its effectiveness and
safety.IndevelopedcountriessuchastheUnitedKing-
domandtheUnitedStates,thestrengthofgovernmen-
tal measures to control influenza A/H1N1 has been
much weaker that in Hong Kong—Hong Kong had
exercised quarantine measures and still recommends
closureofschoolswiththerateofsickleavereachingor
exceeding 10%.
33 The results also suggest that as the
scientific evidence is not available, expected uptake
of A/H1N1 vaccination in the general populations of
different countries would be low.
The results provide some insights into different
international settings, with important implications.
Governments want to promote A/H1N1 vaccination
in the general population and need to understand bar-
riers and facilitators for its acceptability before imple-
menting vaccination on a full scale. From our results it
seemsthatfreeorlowcostvaccinationneedstobepro-
vided to achieve a high rate of vaccination against A/
H1N1. More importantly, the general public has to be
convinced about the vaccine’s efficacy and safety as
misconceptions may exist about what the scientific
data show. Good communication between health
workers and the public is therefore a prerequisite for
a successful A/H1N1 vaccination programme target-
ing the general population. Acceptability studies and
real time monitoring are crucial for the success of such
programmes.
Variables
No (%) of participants
(n=301)
Don’tk n o w 67 (22)
Perceived side effects:
None or a few 162 (54)
Quite a lot or severe 49 (16)
Don’tk n o w 88 (29)
Vaccination against influenza A/H1N1 should be universal in Hong Kong:
Completely not necessary 95 (32)
Not quite necessary 146 (49)
Quite necessary or highly necessary 49 (16)
Don’tk n o wo ru n s u r e 1 1( 4 )
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ratewaslowerthan80%,althoughcomparabletothose
ofotherrelevantpublishedstudies.
17273435Thesexand
age distributions of the sample were comparable to
those of the census data.
36 In this sample, 45% of the
participants were men (census data 46%), 25% were
aged less than 30 years (census data 25%), 21% aged
30-39 (census data 24%), 29% aged 40-49 (census data
27%), and 25% aged 50-60 (census data 24%). Sec-
ondly, Hong Kong went through a unique experience
with the outbreak of severe acute respiratory syn-
drome, the results of the current study may not be
applicable to the situations in other countries. Some
observations about A/H1N1 vaccination may, how-
ever, be shared among countries. Thirdly, this study
could only document the willingness of people to
accept vaccination against influenza A/H1N1, which
may not necessarily reflect their actual behaviour.
Fourthly, we did not record participants’ chronic dis-
easestatus;thosewithchronicdiseasemayhavediffer-
ent intentions from the rest of the general population.
Conclusions
Participants did not consider universal vaccination
against A/H1N1 to be necessary. Efficacy and safety
data are needed to enhance uptake. Cost is important
althoughourstudysuggeststhatmostofthepopulation
wouldnottakeupvaccinationagainstA/H1N1.Asthe
A/H1N1vaccineisnewandmajorplansregardingthe
vaccine have been made in many countries, further
research is warranted. Further studies should also
monitor the level and factors predicting intentions
towards A/H1N1 vaccination longitudinally in differ-
ent risk groups as well as in the general population.
International comparisons are also warranted. Such
studies would improve the understanding of vaccina-
tion against different types of influenza related dis-
eases.
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